SERA (Sera Prognostics) Growth Rank: 8 (As of Aug. 13, 2026) — 11% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SERA Sera Prognostics Inc SERA
71 GF Score
Price $2.04
GF Value $1.81
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Sera Prognostics Growth Rank?

Sera Prognostics SERA +0.50% 71 Growth Rank is 8 as of Aug. 13, 2026, which is 11% below its 10-year median of 9.00. GuruFocus rates SERA with a GF Score™ of 71/100 and a GF Value™ of $1.81 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Sera Prognostics has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sera Prognostics Growth Rank Related Terms

SERA vs ZOMDF, OM, LNSR: Growth Rank Comparison

For the Medical Devices subindustry, Sera Prognostics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sera Prognostics Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Growth Rank falls into.


SERA
71GF Score
Sera Prognostics Inc SERA
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 8 mean?
Sera Prognostics (SERA) has a Growth Rank of 8 as of Aug. 13, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sera Prognostics and its competitors. This is 11% below median its historical median of 9.00. Over the past decade, Sera Prognostics' Growth Rank has ranged from 8.00 to 9.00.
Is Sera Prognostics' Growth Rank too high?
Sera Prognostics' current Growth Rank of 8 is 11% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 9.00. Overall, Sera Prognostics has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' Growth Rank compare to ZOMDF and OM?
Sera Prognostics' Growth Rank of 8 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sera Prognostics' own Growth Rank has ranged from 8.00 to 9.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current Growth Rank is 8, which is 11% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.81, compared to a current price of $2.04 — trading 12.7% above its estimated fair value. The current Growth Rank is 8, which is 11% below median its 10-year median of 9.00. Sera Prognostics' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sera Prognostics (SERA), the current Growth Rank is 8 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sera Prognostics (SERA) Overvalued in 2026?

Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued. The current stock price of $2.04 is trading 12.7% above its estimated GF Value™ of $1.81. GuruFocus considers Sera Prognostics to be Modestly Overvalued.

Key valuation signals for SERA:

  • Growth Rank: 8 (11% below median its 10-year median of 9.00)
  • GF Value™: $1.81 vs. price of $2.04 (12.7% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sera Prognostics Business Description

Address 2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
71GF Score

Get the complete analysis for SERA

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.04
Price
$1.81
GF Value